^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Mesothelin-targeted antibody-drug conjugate

    Related drugs:
    8d
    SGNMesoC2-001: A Study of SGN-MesoC2 in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=19, Active, not recruiting, Seagen, a wholly owned subsidiary of Pfizer | Recruiting --> Active, not recruiting | N=365 --> 19
    Enrollment closed • Enrollment change
    13d
    RC88 in Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer (clinicaltrials.gov)
    P2, N=43, Completed, RemeGen Co., Ltd. | Recruiting --> Completed | N=88 --> 43 | Trial completion date: Dec 2026 --> Dec 2025 | Trial primary completion date: Jun 2026 --> Dec 2025
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date • Platinum resistant
    |
    MSLN (Mesothelin)
    |
    misitatug blivedotin (RC88)
    13d
    A Phase I /IIa Study of RC88-ADC in Subjects With Advanced Malignant Solid Tumors (clinicaltrials.gov)
    P1/2, N=198, Completed, RemeGen Co., Ltd. | Recruiting --> Completed
    Trial completion
    |
    MSLN (Mesothelin)
    |
    misitatug blivedotin (RC88)
    29d
    A Study to Assess the Safety and Tolerability of RC88 for Patients With Advanced Solid Tumours (clinicaltrials.gov)
    P1/2, N=41, Completed, RemeGen Co., Ltd. | Active, not recruiting --> Completed | Phase classification: P1 --> P1/2 | N=81 --> 41 | Trial primary completion date: Jun 2025 --> Nov 2025
    Trial completion • Phase classification • Enrollment change • Trial primary completion date
    |
    MSLN (Mesothelin)
    |
    misitatug blivedotin (RC88)
    3ms
    Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma (clinicaltrials.gov)
    P1/2, N=49, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Sep 2025 --> Sep 2026
    Trial completion date
    |
    PD-L1 (Programmed death ligand 1) • MSLN (Mesothelin)
    |
    Keytruda (pembrolizumab) • anetumab ravtansine (BAY 94-9343)
    5ms
    Mesothelin-directed protein-drug conjugates for mesothelin-low solid tumor therapy. (PubMed, Nat Commun)
    Combination therapy with PD-1 blockade further promotes long-term immunological memory formation by activation of dendritic cells and reprogramming of the tumor microenvironment. These findings highlight the translational potential of DARPin-DC and its promising prospects for clinical combination with immunotherapies in the treatment of solid tumors, including refractory pancreatic cancer.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    MSLN (Mesothelin)
    5ms
    Expression and Prognostic Significance of Different Antibody-Drug Conjugate Target Proteins in Urachal Carcinoma. (PubMed, Clin Genitourin Cancer)
    Our findings confirm that UrC has the potential to be treated by ADC. Trop2 has the highest high expression rate in UrC and is associated with a worse prognosis, which may be a potential target for ADC therapy for UrC.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • CLDN18 (Claudin 18) • MSLN (Mesothelin) • NECTIN4 (Nectin Cell Adhesion Molecule 4) • TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
    7ms
    Advancing Antibody-Drug Conjugates: Precision Oncology Approaches for Breast and Pancreatic Cancers. (PubMed, Cancers (Basel))
    In TNBC, ADCs such as sacituzumab govitecan and trastuzumab deruxtecan have improved progression-free survival in advanced cases. While ADCs have significantly advanced treatment options in TNBC, PDAC remains a difficult target due to its stroma-rich microenvironment and lack of high-density, tumor-specific antigens. This article emphasizes the need for tailor-made ADC designs to enhance results in various types of cancers and provides valuable insight into future advancements in precision oncology.
    Review • Journal
    |
    MSLN (Mesothelin) • MUC1 (Mucin 1)
    |
    Enhertu (fam-trastuzumab deruxtecan-nxki) • Trodelvy (sacituzumab govitecan-hziy)
    9ms
    Evaluating therapeutic plasma exchange and protease inhibitors as mechanisms to reduce soluble mesothelin. (PubMed, Sci Rep)
    We investigated the effects of sMSLN on anetumab, an antibody-based therapy against MSLN, anetumab ravtansine, an antibody drug conjugate, and mechanisms to decrease sMSLN...Overall, sMSLN could represent a predictive biomarker for MSLN directed therapies. TPE may be more reliable than PIs to reduce sMSLN and ultimately restore sensitivity to these therapies in patients with high sMSLN.
    Journal
    |
    MSLN (Mesothelin)
    |
    anetumab ravtansine (BAY 94-9343)
    11ms
    NCI10208: Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer (clinicaltrials.gov)
    P1, N=74, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jan 2025 --> Jan 2026 | Trial primary completion date: Jan 2025 --> Jan 2026
    Trial completion date • Trial primary completion date • Tumor mutational burden
    |
    MSLN (Mesothelin)
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • gemcitabine • anetumab ravtansine (BAY 94-9343) • ABP 206 (nivolumab biosimilar)
    11ms
    A Study of SGN-MesoC2 in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=365, Recruiting, Seagen Inc. | Trial completion date: Nov 2028 --> Feb 2029 | Trial primary completion date: Nov 2028 --> Feb 2028
    Trial completion date • Trial primary completion date